Nektar wins $90M from Lilly in a licensing fight over rezpeg — far short of the roughly $1B it sought. Lilly plans to appeal.
Alnylam alumni-led City Therapeutics files for a Nasdaq IPO under CTY, with $172M in cash and a Phase 1 factor XI siRNA.
Clive Meanwell and John Maraganore's Corsera Health is developing a once-yearly siRNA shot to prevent heart disease in ...
Endpoints News announces the winners of the 2026 Endpoints 11 awards: The best and most exiting biotech startups of the year.
FDA approved Mirum's Atebrioz (zilurgisertib) for FOP, a rare disease turning muscle to bone, joining Ipsen's Sohonos & ...
SonoThera is using ultrasound and microbubbles to push full-length dystrophin into muscle, with a $125M Series B and a 2027 ...
Endpoints 11 winner Stipple Bio is aiming to be part of the future generation of therapies used for deadly pancreatic cancer.
Vivodyne, backed by about $80M, grows vascularized human tissues to screen drugs as the FDA and NIH push alternatives to animal testing.
Brian Armstrong, Blake Byers Headquarters South San Francisco, CA Total raised $682M Key investors Kleiner Perkins, Founders ...
On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...
Weihao Xu built Kali Therapeutics with $18M, no lab and Chinese vendors — then sold its lead T cell engager to Sanofi for ...
Doudna-co-founded Azalea Therapeutics aims to enter the clinic next year with a CRISPR-based in vivo CAR-T therapy for blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results